Marion Garnier
University of Auvergne
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marion Garnier.
Therapeutics and Clinical Risk Management | 2011
Ludovic Samalin; Marion Garnier; Pierre-Michel Llorca
Lurasidone is a new second-generation antipsychotic approved in October 2010 by the Food and Drug Administration for the treatment of schizophrenia. Like other second-generation antipsychotics, lurasidone is a powerful antagonist of D2 dopamine and 5HT2A serotonin receptors, but differs from the other second-generation antipsychotics in its action profile for certain receptors. Lurasidone is the second-generation antipsychotic with the greatest affinity for 5HT7 receptors and has a high affinity for 5HT1A serotonin receptors, compatible with favorable effects on cognitive function and an antidepressant action. By contrast, lurasidone has a low affinity for and α1 α2C-adrenergic and 5HT2C serotonin receptors, and no affinity for histaminergic H1 or muscarinic M1 receptors, suggesting a better tolerability profile than the other second-generation antipsychotics. Lurasidone has demonstrated its efficacy in several short-term trials in acute schizophrenia, promptly and significantly reducing total Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale scores compared with placebo. Several long-term studies are in progress to assess its efficacy in the maintenance treatment of schizophrenic patients. The efficacy of lurasidone with regard to cognitive functions and depressive symptoms seems good, but requires further work. Lurasidone differs from the other second-generation antipsychotics by having a good tolerability profile, in particular for cardiometabolic tolerability. However, it seems to have a significant although moderate link with the occurrence of akathisia, extrapyramidal symptoms, and hyperprolactinemia at the start of treatment. This tolerance profile greatly broadens the scope of second-generation antipsychotics and so supports the view of some authors that the term “second-generation antipsychotic” is now outdated. Other therapeutic perspectives of lurasidone are assessed here, in particular bipolar depression.
Presse Medicale | 2016
Thomas Charpeaud; Fanny Moliere; Maxime Bubrovszky; Frédéric Haesebaert; Najib Allaïli; Rémy Bation; Isabel Nieto; Raphaëlle Richieri; Ghassen Saba; Frank Bellivier; Djamila Bennabi; Jérôme Holtzmann; Vincent Camus; Philippe Courtet; Pierre Courvoisier; Thierry d’Amato; Olivier Doumy; Marion Garnier; Thierry Bougerol; Christophe Lançon; Emmanuel Haffen; Marion Leboyer; Pierre-Michel Llorca; Guillaume Vaiva; Wissam El-Hage; Bruno Aouizerate
Switching antidepressant medication may be helpful in depressed patients having no benefit from the initial antidepressant treatment. Before considering switching strategy, the initial antidepressant treatment should produce no therapeutic effect after at least 4 weeks of administration at adequate dosage. Choosing an antidepressant of pharmacologically distinct profile fails to consistently demonstrate a significant superiority in terms of effectiveness over the switching to another antidepressant within the same pharmacological class. Augmenting SSRI/SNRIs with mirtazapine/mianserin has become the most recommended strategy of antidepressant combinations. Augmenting SSRI with tricyclic drugs is now a less recommended strategy of antidepressant combinations given the increased risk for the occurrence of pharmacokinetic drug-drug interactions and adverse effects.
International Journal of Molecular Sciences | 2016
Ludovic Samalin; Marion Garnier; C. Auclair; Pierre-Michel Llorca
The purpose of this study was to identify clinician characteristics associated with higher prescription rates of long-acting injectable (LAI) antipsychotics, as well as the sources that influence medical decision-making regarding the treatment of schizophrenia. We surveyed 202 psychiatrists during six regional French conferences (Bordeaux, Lyon, Marseille, Nice, Paris, and Strasbourg). Data on the characteristics of practice, prescription rates of antipsychotic, and information sources about their clinical decisions were collected. Most psychiatrists used second-generation antipsychotics (SGAs), and preferentially an oral formulation, in the treatment of schizophrenia. LAI SGAs were prescribed to 30.4% of schizophrenic patients. The duration and type of practice did not influence the class or formulation of antipsychotics used. The clinicians following the higher percentage of schizophrenic patients were associated with a higher use of LAI antipsychotics and a lower use of oral SGAs. Personal experience, government regulatory approval, and guidelines for the treatment of schizophrenia were the three main contributing factors guiding clinicians’ decision-making regarding the treatment of schizophrenia. The more clinicians follow schizophrenic patients, the more they use LAI antipsychotics. The development of specialized programs with top specialists should lead to better use of LAI antipsychotics in the treatment of schizophrenia.
Frontiers in Psychiatry | 2017
Djamila Bennabi; Emmanuel Haffen; Marion Garnier; Frank Bellivier; Thierry Bourgerol; Vincent Camus; Thierry d’Amato; Olivier Doumy; Frédéric Haesebaert; Jérôme Holtzmann; Christophe Lançon; Philippe Vignaud; Fanny Moliere; Isabel Nieto; Raphaëlle Richieri; Philippe Domenech; Corentin Rabu; Luc Mallet; Liova Yon; Laurent Schmitt; Florian Stephan; Guillaume Vaiva; Michel Walter; Pierre-Michel Llorca; Philippe Courtet; Marion Leboyer; Wissam El-Hage; Bruno Aouizerate
Background Major depression is characterized by (i) a high lifetime prevalence of 16–17% in the general population; (ii) a high frequency of treatment resistance in around 20–30% of cases; (iii) a recurrent or chronic course; (iv) a negative impact on the general functioning and quality of life; and (v) a high level of comorbidity with various psychiatric and non-psychiatric disorders, high occurrence of completed suicide, significant burden along with the personal, societal, and economic costs. In this context, there is an important need for the development of a network of expert centers for treatment-resistant depression (TRD), as performed under the leadership of the Fondation FondaMental. Methods The principal mission of this national network is to establish a genuine prevention, screening, and diagnosis policy for TRD to offer a systematic, comprehensive, longitudinal, and multidimensional evaluation of cases. A shared electronic medical file is used referring to a common exhaustive and standardized set of assessment tools exploring psychiatric, non-psychiatric, metabolic, biological, and cognitive dimensions of TRD. This is paralleled by a medico-economic evaluation to examine the global economic burden of the disease and related health-care resource utilization. In addition, an integrated biobank has been built by the collection of serum and DNA samples for the measurement of several biomarkers that could further be associated with the treatment resistance in the recruited depressed patients. A French observational long-term follow-up cohort study is currently in progress enabling the extensive assessment of resistant depressed patients. In those unresponsive cases, each expert center proposes relevant therapeutic options that are classically aligned to the international guidelines referring to recognized scientific societies. Discussion This approach is expected to improve the overall clinical assessments and to provide evidence-based information to those clinicians most closely involved in the management of TRD thereby facilitating treatment decisions and choice in everyday clinical practice. This could contribute to significantly improve the poor prognosis, the relapsing course, daily functioning and heavy burden of TRD. Moreover, the newly created French network of expert centers for TRD will be particularly helpful for a better characterization of sociodemographic, clinical, neuropsychological, and biological markers of treatment resistance required for the further development of personalized therapeutic strategies in TRD.
Presse Medicale | 2016
Olivier Doumy; Djamila Bennabi; Wissam El-Hage; Najib Allaïli; Rémy Bation; Frank Bellivier; Jérôme Holtzmann; Maxime Bubrovszky; Vincent Camus; Thomas Charpeaud; Pierre Courvoisier; Thierry d’Amato; Marion Garnier; Frédéric Haesebaert; Thierry Bougerol; Christophe Lançon; Fanny Moliere; Isabel Nieto; Raphaëlle Richieri; Ghassen Saba; Philippe Courtet; Guillaume Vaiva; Marion Leboyer; Pierre-Michel Llorca; Bruno Aouizerate; Emmanuel Haffen
Lithium is among the most classically recommended add-on therapeutic strategy for the management of depressive patients showing unsuccessful response to standard antidepressant medications. The effectiveness of the add-on strategy with lithium requires achieving plasma levels above 0.5 mEq/L. Mood-stabilizing antiepileptic drugs such as carbamazepine, valproate derivatives or lamotrigine have not demonstrated conclusive therapeutic effects for the management of depressive patients showing unsuccessful response to standard antidepressant medications. Thyroid hormones are considered among the currently recommended add-on therapeutic strategy for the management of depressive patients showing unsuccessful response to standard antidepressant medications. The effectiveness of the add-on strategy with thyroid hormones requires achieving plasma concentration of TSH close to the lower limits at the normal range (0.4 μUI/L) or even below it. Second-generation antipsychotics such as aripiprazole or quetiapine have consistently demonstrated significant therapeutic effects for the management of depressive patients showing unsuccessful response to standard antidepressant medications. Second-generation antipsychotics however require the careful monitoring of both cardiovascular and metabolic adverse effects.
Presse Medicale | 2016
Thomas Charpeaud; Fanny Moliere; Maxime Bubrovszky; Frédéric Haesebaert; Najib Allaïli; Rémy Bation; Isabel Nieto; Raphaëlle Richieri; Ghassen Saba; Frank Bellivier; Djamila Bennabi; Jérôme Holtzmann; Camus; Philippe Courtet; Pierre Courvoisier; Thierry d'Amato; Olivier Doumy; Marion Garnier; Thierry Bougerol; Christophe Lançon; Emmanuel Haffen; Marion Leboyer; Pierre-Michel Llorca; Guillaume Vaiva; Wissam El-Hage; Bruno Aouizerate
Switching antidepressant medication may be helpful in depressed patients having no benefit from the initial antidepressant treatment. Before considering switching strategy, the initial antidepressant treatment should produce no therapeutic effect after at least 4 weeks of administration at adequate dosage. Choosing an antidepressant of pharmacologically distinct profile fails to consistently demonstrate a significant superiority in terms of effectiveness over the switching to another antidepressant within the same pharmacological class. Augmenting SSRI/SNRIs with mirtazapine/mianserin has become the most recommended strategy of antidepressant combinations. Augmenting SSRI with tricyclic drugs is now a less recommended strategy of antidepressant combinations given the increased risk for the occurrence of pharmacokinetic drug-drug interactions and adverse effects.
Presse Medicale | 2016
Jérôme Holtzmann; Raphaëlle Richieri; Ghassen Saba; Najib Allaïli; Rémy Bation; Fanny Moliere; Isabel Nieto; Frank Bellivier; Djamila Bennabi; Maxime Bubrovszky; Vincent Camus; Thomas Charpeaud; Pierre Courvoisier; Frédéric Haesebaert; Olivier Doumy; Philippe Courtet; Wissam El-Hage; Marion Garnier; Thierry d’Amato; Christophe Lançon; Marion Leboyer; Pierre-Michel Llorca; Guillaume Vaiva; Thierry Bougerol; Bruno Aouizerate; Emmanuel Haffen
Post-Print | 2016
Thomas Charpeaud; Fanny Moliere; Maxime Bubrovszky; Frédéric Haesebaert; Najib Allaïli; Rémy Bation; Isabel Nieto; Raphaëlle Richieri; Ghassen Saba; Frank Bellivier; Djamila Bennabi; Jérôme Holtzmann; Vincent Camus; Philippe Courtet; Pierre Courvoisier; Thierry d'Amato; Olivier Doumy; Marion Garnier; Thierry Bougerol; Christophe Lançon; Emmanuel Haffen; Marion Leboyer; Pierre-Michel Llorca; Guillaume Vaiva; Wissam El-Hage; Bruno Aouizerate
Post-Print | 2016
Olivier Doumy; Djamila Bennabi; Wissam El-Hage; Najib Allaïli; Rémy Bation; Frank Bellivier; Jérôme Holtzmann; Maxime Bubrovszky; Vincent Camus; Thomas Charpeaud; Pierre Courvoisier; Thierry d'Amato; Marion Garnier; Frédéric Haesebaert; Thierry Bougerol; Christophe Lançon; Fanny Moliere; Isabel Nieto; Raphaëlle Richieri; Ghassen Saba; Philippe Courtet; Guillaume Vaiva; Marion Leboyer; Pierre-Michel Llorca; Bruno Aouizerate; Emmanuel Haffen
/data/revues/07554982/unassign/S075549821600066X/ | 2016
Ghassen Saba; Isabel Nieto; Rémy Bation; Najib Allaïli; Djamila Bennabi; Fanny Moliere; Raphaëlle Richieri; Jérôme Holtzmann; Maxime Bubrovszky; Vincent Camus; Thomas Charpeaud; Philippe Courtet; Pierre Courvoisier; Frédéric Haesebaert; Olivier Doumy; Wissam El-Hage; Marion Garnier; Thierry d’Amato; Thierry Bougerol; Christophe Lançon; Emmanuel Haffen; Pierre-Michel Llorca; Guillaume Vaiva; Frank Bellivier; Marion Leboyer; Bruno Aouizerate